NFE2L2 and multiple sclerosis: Also, the DMF, a well known inducer of Nrf2 already used in multiple sclerosis treatment and recently proposed as therapy in PD [20], led to 2- and 6-fold increases of Nrf2 mRNA (A) and protein expression (B, C) in 30 μM-treated shFxn (24 h).